Cocrystal Other Stockholder Equity from 2010 to 2025

COCP Stock  USD 1.48  0.05  3.50%   
Cocrystal Pharma Other Stockholder Equity yearly trend continues to be relatively stable with very little volatility. Other Stockholder Equity is likely to grow to about 413.3 M this year. During the period from 2010 to 2025, Cocrystal Pharma Other Stockholder Equity destribution of quarterly values had r-value of  0.89 from its regression line and median of  254,932,000. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2007-09-30
Previous Quarter
342.6 M
Current Value
342.8 M
Quarterly Volatility
142.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
  
Check out the analysis of Cocrystal Pharma Correlation against competitors.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Latest Cocrystal Pharma's Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Cocrystal Pharma over the last few years. It is Cocrystal Pharma's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cocrystal Pharma's overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Cocrystal Other Stockholder Equity Regression Statistics

Arithmetic Mean202,741,266
Coefficient Of Variation83.64
Mean Deviation140,261,504
Median254,932,000
Standard Deviation169,568,231
Sample Variance28753.4T
Range572.8M
R-Value0.89
Mean Square Error6589T
R-Squared0.79
Slope31,578,794
Total Sum of Squares431300.8T

Cocrystal Other Stockholder Equity History

2025413.3 M
2024393.6 M
2023342.3 M
2022337.5 M
2021336.5 M
2020297.3 M
2019260.9 M

About Cocrystal Pharma Financial Statements

Cocrystal Pharma shareholders use historical fundamental indicators, such as Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Stockholder Equity393.6 M413.3 M

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.